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Summary A 45-year-old premenopausal woman was admitted with acute myocardial infarc-
tion. Her serum estrogen level was decreased because of leuprorelin acetate administration,
3 months prior to admission for the treatment of uterine myoma. Emergency coronary
angiography revealed diffuse narrowing of the distal half of the left anterior descendingEstrogen;
Risk factors;
Gender-related
artery (LAD). The second coronary angiography after anti-anginal medication revealed sig-
niﬁcant improvement in LAD narrowing, which suggested prolonged coronary vasospasm. She
had no coronary risk factors except for a positive family history. This case suggests that a
decreased serum estrogen level could cause ischemic heart disease even in premenopausal
women.
Car© 2010 Japanese College of1. Introduction
It is well known that premenopausal women show a low
incidence of ischemic heart disease [1]. To explain this,
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t has been suggested that estrogens have cardioprotective
ffects. Leuprorelin acetate, a gonadotropin-releasing hor-
one, acts as a potent inhibitor of gonadotropin secretion
hen therapeutic doses are given continuously. It results
n decreased levels of luteinizing hormone (LH) as well as
ollicle-stimulating hormone (FSH), and subsequently sup-
resses gonadal sex steroid production. Therefore, it is
sed to treat uterine myoma, endometriosis, prostate can-
er, and breast cancer. In premenopausal women treated
ith leuprorelin acetate, estrogens are reduced to post-
enopausal levels.
Published by Elsevier Ireland Ltd. All rights reserved.
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Figure 1 The 12-lead electrocardiograms in the present case.
During chest pain, it revealed ST segment elevation in leads II,
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It is known that leuprorelin acetate is associated with
ngina in men, but few cases of ischemic heart disease in
omen undergoing treatment with leuprorelin acetate have
een reported [2]. In this paper, we describe a case of acute
yocardial infarction in a premenopausal woman with a
ecreased serum level of estrogen due to treatment with
euprorelin acetate.
. Case report
45-year-old premenopausal woman, who had never been
regnant, was admitted to our hospital with continuous
nterior chest pain for 2 h at rest after work-related emo-
ional stress. She had been diagnosed with uterine myoma
t the age of 35 years. She showed a normal menstrual
ycle (almost once a month) and suffered from dysmenor-
hea with myoma uterus. So, she had been treated with
euprorelin acetate intramuscularly, once every 4 weeks
t a dose of 3.75mg, for 3 months prior to admission at
he age of 45 years. She had no history of anginal attack
efore treatment with leuprorelin acetate. She was a non-
moker and had no prior history of cardiovascular disease,
awasaki disease, aortitis, or collagen diseases. She had
ever taken a contraceptive drug. Her family history was
ound to be positive for ischemic heart disease; her grand-
other and two uncles had ischemic heart disease. However,
one of her family had a history of diabetes, hypertension, or
yperlipidemia.
When she visited her family doctor with anterior chest
ain, 12-lead electrocardiogram (ECG) showed ST elevation
n leads II, III, aVF, and V2 through V6 (Fig. 1A). She was
eferred to our hospital for further evaluation. At the time
f admission, no physical abnormality was observed. How-
ver blood chemistry revealed a slight increase in the level
f creatinine-phosphokinase and positive serum troponin-T.
ublingual administration of nitroglycerin tablets reduced
er chest pain, and 12-lead ECG showed an improvement
n ST elevation (Fig. 1B). Transthoracic echocardiography
evealed mild hypokinesis of the anterior apical portion
f the left ventricle. Immediately, continuous drip-infusion
f isosorbide dinitrate (ISDN) was started and emergency
ardiac catheterization was performed. It revealed 90% nar-
owing only in the distal half of the left anterior descending
rtery (LAD) (Fig. 2B and C) but no signiﬁcant stenosis
n the right coronary artery (RCA) (Fig. 2A) or left cir-
umﬂex artery (LCX) (Fig. 2B). Additional intracoronary
njection of ISDN (3mg) and nicorandil (6mg) did not
mprove the stenosis. Despite severe stenosis of the LAD,
hrombolysis In Myocardial Infarction (TIMI) 3 ﬂow was
bserved and her symptoms were signiﬁcantly reduced.
herefore, percutaneous coronary intervention was not
erformed.
She was treated with the continuous intravenous
dministration of heparin sodium and ISDN. Addition-
lly, she was orally administered diltiazem (200mg/day),
spirin (100mg/day), nicorandil (15mg/day), and isosor-
ide mononitrate (40mg/day). Laboratory tests revealed an
ncreased level of creatinine-phosphokinase (708 IU/l) 5 h
fter admission. On the second hospital day, 12-lead ECG
howed negative T waves in II, III, aVF, and V3 through V6
eads (Fig. 1C). Her clinical course was uneventful. Tread-
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SII, aVF and V2 through V6 (A). Nitroglycerin reduced chest pain
nd improved ST segment elevation (B). On the 2nd day (C) and
fter 2 weeks (D), negative T waves increased.
ill exercise stress testing performed 2 weeks later showed
negative result for ischemia. Three weeks after admission,
ardiac catheterization performed using the same medi-
ations as above revealed signiﬁcant improvement of the
arrowed lumen of the LAD (Fig. 2D). We did not perform a
oronary vasospasm provocation test based on the patient’s
ishes.
Further evaluations of coronary risk factors were per-
ormed. Computed tomography of the chest revealed no
vidence of vasculitis including aortitis. The results of
aboratory tests are shown in Table 1. Two weeks after
dmission, plasma glucose levels after a 75 g oral glucose
oad were 86mg/dl on fasting (insulin level was 11.8U/ml),
04mg/dl at 60min, and 125mg/dl at 120min (insulin level
as 56.9U/ml), and homeostasis model assessment for
nsulin resistance (HOMA-IR) was 2.5, which indicated a nor-
al glucose tolerance with insulin resistance. No evidence
f collagen diseases including vasculitis or a deﬁciency of
oagulation factor was noted. The serum level of estrogen
as decreased because of the use of leuprorelin acetate
Table 1). She stopped using leuprorelin acetate, and, 3
onths later, regained recovery of the menstrual cycle.
even months later, her serum estrogen level was 35 pg/ml
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Figure 2 Emergency coronary angiograms on the ﬁrst hospital day showed no stenosis in the right coronary artery (RCA) (A) or
ing in
rrow
) an
3
Tleft circumﬂex coronary artery (LCA) (B), but revealed narrow
the ﬁrst hospital day, emergency coronary angiogram showed na
Gradual improvement in stenosis was observed after 3 weeks (D
and improved to that of premenopausal women. Her coro-
nary angiography also revealed a normal appearance of
the LAD (Fig. 2E). Now, 3 years after stopping treat-
ment with leuprorelin acetate, the estrogen (E2) level is
33 pg/ml, the FSH level is 21.64IU/ml and the LH level is
3.74IU/ml. She shows a normal menstrual cycle (almost
once a month), and suffers from dysmenorrhea with myoma
uterus.
b
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ithe distal half of the left anterior descending artery (B). On
ing at the distal half of the left anterior descending artery (C).
d 6 months (E).
. Discussion
his case was diagnosed as acute myocardial infarction
ased on the positive ﬁndings of typical chest pain,
hanges in electrograms, an elevated level of creatine-
hosphokinase, and positive troponin-T. The 12-lead ECG
howed ST elevation not only in leads V2 through V6 but also
n inferior leads (Fig. 1A), because the apical area of the left
e174
Table 1 The results of laboratory tests on patient admis-
sion.
WBC 6400/l
Hb 15.3 g/dl
Plt 19.1× 104/l
TP 7.6 g/dl
GOT 22 IU/l
GPT 16 IU/l
CPK 209 IU/l
CK-MB 29 IU/l
LDH 202 IU/l
BUN 9.4mg/dl
Cr 0.5mg/dl
UA 3.4mg/dl
TC 189mg/d
TG 72mg/dl
LDL-c 94mg/dl
HDL-c 65mg/dl
LP(a) 25.0mg/dl
BS 123mg/dl
HbA1c 4.9%
FDP 2.25g/ml
D-dimer 0.07g/ml
AT III 92%
ProteinC 112%
ProteinS 75%
CRP <0.01g/dl
ANA <40
RF 4 IU/ml
PR3-ANCA <3.5U/ml
MPO-ANCA <1.3U/ml
AntiCLAb <8.0U/ml
AntiCL2Ab <0.7U/ml
Testosterone 0.15 ng/ml
Estradiol <10 pg/ml
Progesterone <0.2 ng/ml
WBC, white blood cell count; Hb, hemoglobin; Plt, platelet;
TP, total protein; GOT, glutamate oxaloacetate transami-
nase; GPT, glutamate pyruvate transaminase; CPK, creatine-
phosphokinase; CK-MB, creatine kinase-MB; LDH, lactate
dehydrogenase; BUN, blood urea nitrogen; Cr, creatinine;
UA, uric acid; TC, total cholesterol; TG, triglyceride; LDL-
c, low-density lipoprotein-cholesterol; HDL-c, high-density
lipoprotein-cholesterol; LP(a), lipoprotein(a); BS, blood sugar;
HbA1c, hemoglobin A1c; FDP, ﬁbrin degradation products;
AT III, antithrombin III; CRP, C-reactive protein; ANA,
antinuclear antibody; RF, rheumatoid factor; PR3-ANCA,
proteinase-3-antineutrophil cytoplastic antibody; MPO-ANCA,
v
a
w
a
i
r
c
d
n
i
m
l
a
p
t
f
g
s
c
h
b
e
d
b
w
o
t
f
i
p
s
r
a
l
a
l
d
n
i
o
e
c
e
w
g
f
v
s
i
S
a
a
t
o
h
W
mmyeloperoxidase-antineutrophil cytoplastic antibody; AntiCLAb,
anticardiolipin antibody IgG; AntiCL2Ab, anticardiolipin anti-
body, cardiolipin antibody 2—glycoprotein-1 complex.
entricle was fed by the culprit lesion of the LAD (Fig. 2B
nd C) rather than by RCA (Fig. 2A) and LCX (Fig. 2B), which
ere relatively small.
Previous clinical investigations reported that young
dults with acute myocardial infarction often angiograph-
cally showed normal coronary arteries [3], frequently
elated to coronary vasospasm [4]. In this case, the ﬁrst
oronary angiography revealed diffuse narrowing in the
istal half of the LAD, but neither coronary dissection
RT. Sasaki et al.
or thrombosis. Although ISDN and nicorandil could not
mmediately improve the LAD stenosis, after anti-anginal
edications, follow-up angiography performed 3 weeks
ater showed improvement of the stenosis, which could be
ttributed to prolonged coronary vasospasm.
The prevalence of coronary vasospasm differs among
opulations, and is higher in Japan than in Western coun-
ries, probably due to genetic as well as environmental
actors [4]. For example, it is reported that various
enetic polymorphisms of the endothelial nitric oxide
ynthase (e-NOS) gene are signiﬁcantly associated with
oronary vasospasm in Japan. In this case, her family
istory of ischemic heart disease might imply these genetic
ackgrounds.
After stopping treatment with leuprorelin acetate, the
strogen level recovered to normal, not high, levels. These
ata along with the FSH and LH levels indicate that she might
e approaching menopause, but she is still a premenopausal
oman with a normal menstrual cycle.
We cannot exclude the possibility that the occurrence
f acute myocardial infarction was incidental during
reatment with leuprorelin acetate, but it is not unlikely
or only the family history to account for myocardial
nfarction like this in premenopausal women. Ordinarily,
remenopausal women without coronary risk factors (e.g.
moking, diabetes mellitus, and hypertension) rarely expe-
ience ischemic heart disease, because of protection by the
nti-atherogenic effects of estrogens. The use of leuprore-
in acetate, through the decrease in estrogens, might
ffect lipid metabolism (e.g. the increase in low-density
ipoprotein-cholesterol) and induce ischemic coronary
isease. However, in this case, the laboratory data showed
o abnormality of the lipid proﬁle.
The beneﬁcial effects of estrogens can account for the
mprovement in endothelial function as well as alteration
f the lipid proﬁle [5]. Experimental studies reported that
strogens, increasing the amount of mRNAs for e-NOS,
ause an increase in the production of nitric oxide as an
ndothelium-derived relaxing factor [6]. In postmenopausal
omen, it was reported that the administration of estro-
en improves endothelium-dependent coronary vasodilator
unction [7,8].
Clinically, in premenopausal women with coronary
asospasm, decreased serum estrogen levels in the men-
trual cycle could be associated with the worsening of
schemia and decreased coronary vasodilator function [9].
imilarly, in postmenopausal women, estrogen levels are
ssociated with the threshold levels of angina with coronary
rtery disease [10].
Therefore, in this case, decreased levels of estrogens due
o the use of leuprorelin acetate, causing the dysfunction
f endothelium-dependent coronary vasodilatation, might
ave resulted in the prolongation of coronary vasospasm.
e should be careful about ischemic heart disease in pre-
enopausal women with a decreased serum estrogen level.eferences
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